Following recent news of Barcelonas campaign to e

first_imgFollowing recent news of Barcelona’s campaign to encourage people to dress ‘appropriately’ when out and about enjoying markets, museums and other public buildings, Skyscanner reveals the travelling public’s attitude toward covering up in various locations.Over 3,000 people voted in the Skyscanner poll which surveyed attitudes towards both men and women wearing swimwear and going topless and shirtless.Whereas 96% of males thought it was fine for females to go topless on beaches, only 87% of females themselves agreed. When asked about appropriate places for females to wear bikinis, 93% of men and women believed it was ok on the beach but only 31% thought it was appropriate in a bar, cafe or restaurant. For men going shirtless, 98% said it was fine on the beach but only 18% said it was acceptable in a supermarket or bar.29% of respondents said that they didn’t want to expose their children to topless beach culture and 21% cited fear of overexposure to UV as their reason for avoiding such places. Other reasons given for disapproval of topless bathing included “it causes offence”, “ogling men” and “encourages voyeurism”.Despite the British being renowned for being reserved, when compared to other European nations, Brits ranked as one of the biggest advocates for topless sunbathing on beaches with 93% in favour. 91% of Italian and 91% of French respondents believed it was ok as did 82% of Swedes. Russians were less keen with only 67% in agreement, but it was the Germans who were the biggest fans with 99% of those surveyed saying that women should be allowed to sunbathe topless.Benjamín Pérez Ulecia, Skyscanner’s Country Manager for Spain said:“Whilst most people believe it’s perfectly acceptable to wear a bikini or walk around shirtless on the beach, it’s a different story in a museum, supermarket or restaurant. The most important thing to remember whilst visiting another country is to respect the local customs and culture. You wouldn’t wander around London’s Tate Gallery in a bikini, and Barcelona’s new ‘bikini ban’ campaign is trying to encourage tourists to dress appropriately for the environment they are in.”ReturnOne wayMulti-cityFromAdd nearby airports ToAdd nearby airportsDepart14/08/2019Return21/08/2019Cabin Class & Travellers1 adult, EconomyDirect flights onlySearch flights Map RelatedBattle of the Sexes as Women-only Toilets Introduced on PlanesPlans by one airline to add women-only toilets to its flights have split opinion59% of travellers want family-only section on flightsA poll carried out by Skyscanner, has revealed that 59% of travellers would like a ‘families only’ section onboard flights.Skyscanner reveals the perfect hotelSkyscanner survey reveals women and men prioritise different features and facilities from their perfect hotellast_img read more

Cuttingedge stem cell therapy proves safe but will it ever be effective

first_img Kyodo News/Contributor/getty images Cutting-edge stem cell therapy proves safe, but will it ever be effective? Clinical work is progressing much more quickly than I expected. By Dennis NormileMar. 15, 2017 , 5:00 PM Masayo Takahashi (second from left) treated macular degeneration with retinal tissue grown from iPS cells. Sign up for our daily newsletter Get more great content like this delivered right to you! Country It’s official: The first use of induced pluripotent stem (iPS) cells in a human has proved safe, if not clearly effective. Japanese researchers reported in this week’s issue of The New England Journal of Medicine (NEJM) that using the cells to replace eye tissue damaged by age-related macular degeneration (AMD) did not improve a patient’s vision, but did halt disease progression. They had described the outcome at conferences, but publication of the details is an encouraging milestone for other groups gearing up to treat diseased or damaged organs with the versatile replacement cells, which are derived from mature tissues.This initial success “is pretty momentous,” says Alan Trounson, a stem cell scientist at the Hudson Institute of Medical Research in Melbourne, Australia. But the broader picture for iPS therapies is mixed, as researchers have retreated from their initial hopes of creating custommade stem cells from each patient’s tissue. That strategy might have ensured that recipients’ immune systems would accept the new cells. But it proved too slow and expensive, says Shinya Yamanaka of Kyoto University in Japan, who first discovered how to create iPS cells and is a co-author of the NEJM paper. He and others are now developing banks of premade donor cells. “Using stocks of cells, we can proceed much more quickly and cost effectively,” he says.Even so, “clinical work is progressing more quickly than I had expected,” says Yamanaka, who did his groundbreaking work just a decade ago. His collaborator on this trial, Masayo Takahashi of the RIKEN Center for Developmental Biology in Kobe, Japan, had a head start. An ophthalmologist, Takahashi was familiar with the ravages of AMD, a condition that progressively damages the macula, the central part of the retina, and is the leading cause of blindness in the elderly. Takahashi started investigating treatments for AMD in 2000, a time when the only cells capable of developing into all the tissues of the body had to be extracted from embryos. But she was stymied by immune reactions to these embryonic stem (ES) cells. When Yamanaka announced that he could induce mature, or somatic cells, to return to an ES cell–like state, Takahashi quickly changed course to develop a treatment based on iPS cells.Her team finally operated on the first patient, a 77-year-old Japanese woman with late-stage AMD, in September 2014. They took a sample of her own skin cells, derived iPS cells, and differentiated them into the kind of retinal cells destroyed by the disease. A surgeon then slipped a small sheet of the cells into the retina of her right eye.An operation on a second patient was called off because a number of minor genetic mutations had crept into his iPS cells during processing, and uncontrolled growth—cancer—has been a worry with such cells. “These changes do not directly induce cancer, but we wanted to make safety the first priority,” Yamanaka says. Also, Takahashi says, AMD drugs had stabilized the patient’s condition so there was no urgency in subjecting him to the risks of surgery, which include hemorrhaging and retinal damage.Immediately after surgery the first patient reported her eyesight was brighter. Takahashi says the surgery halted further deterioration of her eye, even without the drug injections still being used to treat her other eye, and there were no signs of rejection of the graft as of last December. Click to view the privacy policy. Required fields are indicated by an asterisk (*) Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Email Shinya Yamanaka, Kyoto University The result is “a proof of principle that iPS cell–based therapy is feasible,” says Kapil Bharti, a molecular cell biologist at the U.S. National Institutes of Health’s National Eye Institute in Bethesda, Maryland, who is also developing iPS cells for treating AMD. Takahashi says once her team gains more experience with the technique they will extend it to patients with earlier-stage AMD in an effort to preserve vision.Last month, Takahashi won approval to try the procedure on another five patients with late-stage AMD. But this time, instead of using iPS cells derived from each patient, the team will draw on banked cells from a single donor. “It takes time to create iPS cells, and a lot of time for the safety evaluation,” Yamanaka says. It is also costly, at nearly $900,000 to develop and test the iPS cells for the first trial, Takahashi adds.Using donor cells to create the iPS cells will make it more difficult to ensure immune compatibility. But Yamanaka says that donor iPS cells can be matched to patients based on human leukocyte antigen (HLA) haplotypes—sets of cell-surface proteins that regulate immune reactions. HLA-matched cells should require only small doses of immunosuppressive drugs to prevent rejection, Takahashi says—and perhaps none at all for transplantation into the “immune-privileged” eye.Kyoto University’s Center for iPS Cell Research and Application, which Yamanaka heads, has been developing an iPS cell bank. Just 75 iPS cell lines will cover 80% of the Japanese population through HLA matching, he says. Trounson, a past president of the California Institute for Regenerative Medicine, a stem cell funding agency, says banked iPS cells have advantages. Donor iPS cells may be safer than cells derived from older patients, whose somatic cells may harbor mutations. And Jordan Lancaster, a physiologist at the University of Arizona in Tucson, likes the speed of the approach. He is devising patches for heart failure patients based on iPS-derived myocardial cells that will be “premanufactured, cryopreserved, and ready to use at a moment’s notice.”Patient-specific iPS cells will still have clinical uses. For one thing, Bharti says it will be difficult for cell banks to cover all HLA haplotypes. And a patient’s own iPS cells could be used to screen for adverse drug reactions, says Min-Han Tan, an oncologist at Singapore’s Institute of Bioengineering and Nanotechnology, who recently published a report on the approach.Other human trials are not far behind. Yamanaka says his Kyoto University colleague Jun Takahashi (Masayo Takahashi’s husband) will launch trials of iPS-derived cells to treat Parkinson’s disease within 2 years. Bharti hopes to start human trials of iPS cells for a different type of macular degeneration next year. And as techniques for making and growing iPS cells improve, researchers can contemplate treatments requiring not just 100,000 cells or so—the number in Takahashi’s retinal sheets—but millions, as in Lancaster’s heart patches.As clinical use approaches, Takahashi cautions that researchers need to keep public expectations realistic. For now, iPS treatments may help but won’t fully reverse disease, she says. “Regenerative medicine is not going to cure patients in the way they hope.”last_img read more